Conditions for proliferation of human cord blood–derived erythroblasts in serum-free StemSpan medium
Factor . | Concentration . |
|---|---|
| Optimal long-term proliferation | |
| Erythropoietin | 2 U/mL |
| Dex (synthetic glucocorticoid) | 1 μM |
| IGF-1 | 40 ng/mL |
| SCF | 100 ng/mL |
| Cholesterol-rich lipid mix | 40 μg/mL |
| Dihydrotestosterone* | 1 μM |
| Factors without any effect | |
| Interleukin-3 | 1 ng/mL |
| TGF-β | 5 ng/mL |
| Heparin-binding EGF | 20 ng/mL |
| Testosterone† | 1 μM |
| Progesterone | 1 μM |
| Estrogen | 1 μM |
| Cpa (androgen antagonist) | 1 μM |
| Fibronectin-coated plates | 20 ng/mL |
| LY (PI-3-K inhibitor) | 1 μM |
Factor . | Concentration . |
|---|---|
| Optimal long-term proliferation | |
| Erythropoietin | 2 U/mL |
| Dex (synthetic glucocorticoid) | 1 μM |
| IGF-1 | 40 ng/mL |
| SCF | 100 ng/mL |
| Cholesterol-rich lipid mix | 40 μg/mL |
| Dihydrotestosterone* | 1 μM |
| Factors without any effect | |
| Interleukin-3 | 1 ng/mL |
| TGF-β | 5 ng/mL |
| Heparin-binding EGF | 20 ng/mL |
| Testosterone† | 1 μM |
| Progesterone | 1 μM |
| Estrogen | 1 μM |
| Cpa (androgen antagonist) | 1 μM |
| Fibronectin-coated plates | 20 ng/mL |
| LY (PI-3-K inhibitor) | 1 μM |